Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2020-07-07 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Proposed issue of Securities - ANP 5 pages 27.3KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Antisense Therapeutics Limited. It details the number of securities to be issued, the type of issue (placement or other), the proposed issue date, and other related information such as approvals, fees, and conditions. There is no financial data, earnings information, or detailed financial statements included. The document is focused on informing about a capital raising event or change in capital structure. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes.
2020-07-07 English
ShareCafe Small Cap Hidden Gems Webinar Presentation 1
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 25 June 2020 about Antisense Therapeutics' participation in a ShareCafé Small Cap “Hidden Gems” Webinar presentation scheduled for 26 June 2020. It provides details about the webinar, including the focus on clinical trial results and how to register for the event. The document does not contain any financial statements, detailed financial data, or regulatory filings. It is essentially an announcement of an upcoming investor presentation event rather than the presentation itself or a financial report. The document length is short (2325 characters), and it is clearly an announcement of a presentation event. Therefore, the most appropriate classification is Investor Presentation (IP) as it relates to a presentation for investors focusing on company updates and clinical trial progress.
2020-06-24 English
ANP to Present at Webinar Hosted by PPMD in the US 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 17 June 2020 about Antisense Therapeutics presenting final results from its Phase II clinical trial at a webinar hosted by Parent Project Muscular Dystrophy. It describes the trial results, the webinar details, and contact information. The document is relatively short (3793 characters) and serves as an announcement of an upcoming presentation rather than the presentation itself or a detailed financial or regulatory report. There is no financial data, regulatory filing, or detailed report content. It is not an earnings release, annual report, or any other formal financial or regulatory filing. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other categories.
2020-06-16 English
Poster Presentation MDA Virtual Conference 2020 3 pages 180.4KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement dated 11 June 2020 from Antisense Therapeutics. It announces a poster presentation of Phase II clinical trial data for the drug ATL1102 at the Muscular Dystrophy Association Virtual Conference 2020. The text includes detailed clinical trial results, safety and efficacy data, and conclusions about the drug's potential. It is not a full annual or interim financial report, nor is it a regulatory filing or certification. It is a corporate announcement focused on clinical trial results and scientific data rather than financial performance or governance. The document length is 9582 characters, which is substantial and contains detailed data, not just a brief announcement or link to a report. Therefore, it is best classified as a Capital/Financing Update (CAP) because it relates to clinical development progress which is material to the company's capital market communications and investor updates about drug development progress, which can impact financing and valuation. It is not a typical earnings release or investor presentation but fits best under CAP as it updates on a key development milestone relevant to investors and capital markets.
2020-06-10 English
Trial Met Primary & Exceeded Secondary Endpoint Expectations 24 pages 2.2MB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 21 May 2020 from Antisense Therapeutics Limited reporting the final Phase II clinical trial results of their drug ATL1102 for Duchenne Muscular Dystrophy (DMD). The text details the trial's primary and secondary endpoints, safety and tolerability data, efficacy results including motor function and MRI data, expert commentary, and next steps including regulatory submissions and plans for a Phase IIb trial. The document is approximately 15,000 characters long and contains substantive clinical trial results and analysis rather than just an announcement or summary. It is not a financial report, earnings release, or regulatory filing but a detailed clinical trial results announcement. Given the nature of the content and the fact it is an official announcement of clinical trial results, the most appropriate classification is a Regulatory Filing (RNS) as it is a general regulatory announcement about clinical trial results and next steps, not fitting other financial or governance categories.
2020-05-20 English
Trading Halt 2 pages 227.3KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Antisense Therapeutics Limited regarding a trading halt requested under ASX Listing Rule 17.1. It states that the trading halt is pending the release of an announcement about the results of a Phase II clinical trial. The document does not contain any financial data, report content, or detailed financial results. It is a short notice about the trading halt itself, not the actual report or announcement of clinical trial results. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement related to trading status and compliance, rather than a financial report or other specific filing type.
2020-05-19 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.